MDeH has been a consultant to, received grant/research support and honoraria from, and has served on the speakers/advisory boards of AstraZeneca, Lundbeck JA, Janssen-Cilag, Eli Lilly & Co., Pfizer, Sanofi and Bristol-Myers Squibb. DVE has served on the speakers/advisory board of Sanofi. LH is an employee of Bristol-Myers Squibb. AS has served on the speakers/advisory boards of Pfizer, Sanofi-Aventis, Eli Lilly & Co., AstraZeneca, Novo Nordisk and MSD. JP has been a consultant to, received grant/research support and honoraria from, and has served on the speakers/advisory boards of AstraZeneca, Lundbeck JA, Janssen-Cilag, Eli Lilly & Co., Pfizer, Sanofi and Bristol-Myers Squibb. RvW, MW has no conflicts of interest to disclose relative to this article.
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
Article first published online: 6 FEB 2008
© 2008 Blackwell Munksgaard
Volume 10, Issue 2, pages 342–348, March 2008
How to Cite
Van Winkel, R., De Hert, M., Van Eyck, D., Hanssens, L., Wampers, M., Scheen, A. and Peuskens, J. (2008), Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disorders, 10: 342–348. doi: 10.1111/j.1399-5618.2007.00520.x
- Issue published online: 6 FEB 2008
- Article first published online: 6 FEB 2008
- Received 3 June 2006; revised and accepted for publication 15 December 2006
- bipolar disorder;
- metabolic syndrome;
- physical health
Objectives: The presence of metabolic abnormalities is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic abnormalities in disorders other than schizophrenia in which antipsychotic medication is part of routine treatment.
Methods: Sixty consecutive patients with bipolar disorder (BD) at our university psychiatric hospital and affiliate services were entered in an extensive prospective metabolic study including an oral glucose tolerance test. The prevalence of the metabolic syndrome was assessed based on the National Cholesterol Education Program Adult Treatment Protocol (ATP-III) criteria, the adapted ATP-III criteria using a fasting glucose threshold of 100 mg/dL, and the recently proposed criteria from the International Diabetes Federation (IDF).
Results: The analysis of 60 patients showed a prevalence of the metabolic syndrome of 16.7% (ATP-III), 18.3% (adapted ATP-III) and 30.0% (IDF), respectively. A total of 6.7% of the patients met criteria for diabetes and 23.3% for pre-diabetic abnormalities.
Conclusions: The metabolic syndrome and glucose abnormalities are highly prevalent among patients with BD. They represent an important risk for cardiovascular and metabolic disorders. Assessment of the presence and monitoring of metabolic abnormalities and its associated risks should be part of the clinical management of patients with BD.